Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-18
2006-07-18
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S374100
Reexamination Certificate
active
07078426
ABSTRACT:
This invention relates to compounds having the Formula I:or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Het and R5-R8are set in the specification. The invention also is directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
REFERENCES:
patent: 3049438 (1962-08-01), Buell et al.
patent: 3058989 (1962-10-01), Buell et al.
patent: 4072498 (1978-02-01), Moon et al.
patent: 4394514 (1983-07-01), Kruse
patent: 4454337 (1984-06-01), Kruse
patent: 4618681 (1986-10-01), Kadaba et al.
patent: 4639266 (1987-01-01), Heubach et al.
patent: 4962011 (1990-10-01), Aldag et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5602156 (1997-02-01), Kohn et al.
patent: 5607956 (1997-03-01), Boar et al.
patent: 5670533 (1997-09-01), Matsuo et al.
patent: 5744492 (1998-04-01), Kohn et al.
patent: 6057346 (2000-05-01), Kohn et al.
patent: 19 36 760 (1970-01-01), None
patent: 29 10 330 (1980-10-01), None
patent: 0 273 528 (1988-07-01), None
patent: 0 323 841 (1989-07-01), None
patent: 0 323 841 (1990-09-01), None
patent: 0 488 959 (1992-06-01), None
patent: 0 323 841 (1993-08-01), None
patent: 0554829 (1993-08-01), None
patent: 1 081 146 (2001-03-01), None
patent: 2 105 327 (1983-03-01), None
patent: 11 199566 (1999-07-01), None
patent: WO 96/11911 (1996-04-01), None
patent: WO 97/07102 (1997-02-01), None
patent: WO 99/62885 (1999-12-01), None
patent: WO 00/57877 (2000-10-01), None
Arient, J. and Dvo{hacek over (r)}ák, J., “Triphenylmethane dyes. II. Introduction of the triazole group into the triphenylmethane skeleton,”Chem. Abstracts 52:Abstract No. 12401i, The American Chemical Society (1958).
Baud, J., et al., “CGP 31358 binds to a site on the NMDA receptor that is coupled to both the transmitter recognition site and the channel domain,”Neurosci. Lett. 107:184-188, Elsevier Scientific Publishers Ireland Ltd. (1989).
Bensimon, G., et al., “A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis,”New Eng. J. Med. 330:585-591, Massachusetts Medical Society (1994).
Brown, J.B. and Stammers, D.W., “Yellow color images by silver and dye bleaching,”Chem. Abstracts 57:Abstract No. 12673d, The American Chemical Society (1962).
Brown, C.M., et al., “Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia,”Br. J. Pharmacol. 115:1425-1432, Stockton Press (Aug. 1995).
Buchan, A.M., et al., “AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists,”Suppl. I Stroke 24:148-152, Lippincott Williams and Wilkins (1993).
Catterall, W.A., “Structure and Function of Voltage-Sensitive Ion Channels,”Science 242:50-61, American Association for the Advancement of Science (1988).
Catterall, W.A., “Neurotoxins That Act on Voltage-Sensitive Sodium Channels in Excitable Membranes,”Ann. Rev. Pharmacol. Toxicol 20:15-43, Annual Reviews Inc. (1980).
Catterall, W.A., “Common modes of drug action on Na+channels: local anesthetics, antiarrhythmics and anticonvulsants,”Trends Pharmacol. Sci. 8:57-65, Elsevier Science Publishers B.V. (1987).
Cocco, M.T., et al., “Phytotoxic Activity in Pyrazole Derivatives II,”Il Farmaco Ed. Sc. 40:272-284, Societa Italiana Di Scienze Farmaceutiche (1985).
Creveling, C.R., et al., “Batrachotoxin-Induced Depolarization and [3H] Batrachotoxinin-A 20α-Benzoate Binding in a Vesicular Preparation from Guinea Pig Cerebral Cortex,”Mol. Pharmacol. 23:350-358, The American Society for Pharmacology and Experimental Therapeutics (1983).
Dal Monte, D. and Veggetti, P., “Derivatives of pyrazolone and pyrazolyl carbamates,”Chem. Abstracts 53:Abstract No. 8122f, The American Chemical Society (1959).
Denicoff, K.D. et al., “Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey,”J. Clin. Psychiatry 55:70-76, Physicians'Postgraduate Press, Inc. (1994).
Dimmock, J.R., et al., “Evaluation of the thiosemicarbazones of some aryl alkyl ketones and related compounds for anticonvulsant activities,”Eur. J. Med. Chem. 26:529-534, Elsevier Science (1991).
Donaldson, I., “Tegretol: A double blind trial in tinnitus,”J. Laryngol. Otol. 95:947-951, Royal Society of Medicine Press (1981).
Filer, C.N., “Chapter 6, The Preparation and Characterization of Tritiated Neurochemicals,”In:Isotopes in the Physical and Biomedical Sciences, vol. 1, Labelled Compounds (Part A), Buncel, E. and Jones, J.R. eds., pp.156-192, Elsevier Science Publishers B.V. (1987).
J.R. Geigy A.-G., “Diazo dyes,”Chem. Abstracts 60:Abstract No. 12144b, The American Chemical Society (1964).
Graham, S.H., et al., “Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion,”J. Pharmacol. Exp. Ther. 269:854-859, The American Society for Pharmacology and Experimental Therapeutics (1994).
Graham, S.H., et al., “A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia,”J. Pharmacol. Exp. Ther. 276:1-4, The American Society for Pharmacology and Experimental Therapeutics (1996).
Hamill, O.P., et al., “Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches,”Pflügers Arch. 391:85-100, Springer-Verlag (1981).
Hunskaar, S. et al.,“Formalin test in mice, a useful technique for evaluating mild analgesics,”J. Neurosci. Methods 14:69-76, Elsevier Science Publishers B.V.(1985).
Iwasaki, Y., et al., “CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats,”J. Neurosci. 134:21-25, Elsevier Science B.V. (1995).
Kuo, C.-C. and Bean, B.P., “Slow Binding of Phenytoin to Inactivated Sodium Channels in Rat Hippocampal Neurons,”Mol. Pharmacol. 46:716-725, The American Society for Pharmacology and Experimental Therapeutics (1994).
Lam, P.Y.S., et al., “New Aryl/Heteroacryl C-N Bond Cross-coupling Reactions via Arylboronic Acid/Cupric Acetate Arylation,”Tetrahedron Lett. 39:2941-2944, Elsevier Science Ltd. (1998).
Majumdar, B., et al., “An electrocochleographic study of the effects of lignocaine on patients with tinnitus,”Clin. Otolaryngol 8:175-180, Blackwell Scientific Publications (1983).
Magagnoli, R., “1-(p-Benzoylphenyl)-3-alkyl(or benzamido)-5-pyrazolones as color couplers,”Chem. Abstracts 65:Abstract No. 5576g, The American Chemical Society (1966).
Møller, A.R., “Similarities Between Chronic Pain and Tinnitus,”Am. J. Otol. 18:577-585, Lippincott-Raven Publishers (1997).
Neeff, R., “Anilinoanthraquinone dyes,”Chem. Abstracts 63:Abstract No. 11745g, The American Chemical Society (1965).
Ohizumi, Y., et al., “Specific Inhibition of [3H] Saxitoxin Binding to Skeletal Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker,”J. Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Inc. (1986).
Pokorn{grave over (y)}, M. and Haase, J., “Substantive triphenodioxazine dyes containing a naphtho-[1,2-d] triazole nucleus,”Chem. Abstracts 55:Abstract No. 7854i, The American Chemical Society (1961).
Polevoi, L.G., et al., “Relation of aminopyrazole structures to their neurotropic activity,” retrieved from STN, Database Accession No. 69:1557 CAPLUS, Chemical Abstracts Service (1968).
Ragsdale, D.S., et al., “
Hogenkamp Derk J.
Nguyen Phong
Yang Ji
Euro-Celtique S.A.
McKane Joseph K.
Shameem Golam M M
Sterne Kessler Goldstein & Fox
LandOfFree
Aryl substituted pyrazoles, triazoles, and tetrazoles, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl substituted pyrazoles, triazoles, and tetrazoles, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl substituted pyrazoles, triazoles, and tetrazoles, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3610241